The EVERY Co has urged a court in Wisconsin to toss a lawsuit from Onego Bio seeking to invalidate one of EVERY's patents.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or "the Company") for ...
From October 28th to 30th, Kexing Biopharm participated in CPHI Frankfurt 2025, one of the world's most influential pharmaceutical exhibitions, presenting its key product portfolio and international ...
Live Science on MSNOpinion
One molecule could usher revolutionary medicines for cancer, diabetes and genetic disease — but the US is turning its back on it
The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...
As drug development becomes more complex, so do the demands for accurate, reproducible bioanalytical data to prove their ...
News-Medical.Net on MSN
Molecular bumpers and glues rewire GPCR signaling for next-generation medicines
New research led by the University of Minnesota Medical School demonstrates that molecules acting as "molecular bumpers" and "molecular glues" can rewire G protein-coupled receptor (GPCR) signaling, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback